MRK News Alert Merck & Company (MRK) 57.46 12/25/2014 16:09:

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Merck & Company (MRK) 57.46 $MRK

This Cancer Drug War Is Just Getting Started
Brian Orelli, The Motley Fool - Motley Fool - Wed Dec 24, 11:41AM CST
The Food and Drug Administration approved Bristol-Myers Squibb 's Opdivo to treat melanoma on Monday. That's not very surprising given the strong clinical trial data the cancer drug has posted so far. In a trial of 120 patients without any other...
MRK: 57.46 (+0.25), BMY: 59.15 (-0.01)

Bristol-Myers Oncology Drug Opdivo Receives FDA Approval - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 23, 4:45PM CST
Bristol-Myers Squibb Company announced that the FDA has cleared its intravenous human programmed death receptor-1 blocking antibody, Opdivo.
AGN: 210.12 (+0.95), ACT: 254.20 (-1.68), MRK: 57.46 (+0.25), BMY: 59.15 (-0.01)

Merck Falls 2.97% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Tue Dec 23, 3:47PM CST
Merck (NYSE:MRK) traded in a range yesterday that spanned from a low of $57.03 to a high of $59.00. Yesterday, the shares fell 3.0%, which took the trading range below the 3-day low of $58.09 on volume of 14.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
MRK: 57.46 (+0.25)

SmarTrend Watching for Potential Rebound in Shares of Merck After 2.97% Loss
Comtex SmarTrend(R) - Tue Dec 23, 3:46PM CST
Merck (NYSE:MRK) traded in a range yesterday that spanned from a low of $57.03 to a high of $59.00. Yesterday, the shares fell 3.0%, which took the trading range below the 3-day low of $58.09 on volume of 14.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
MRK: 57.46 (+0.25)

Medivation Licenses CureTech's Cancer Drug Pidilizumab - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 23, 3:30PM CST
Medivation (MDVN) exercised its option for pidilizumab (CT-011) from CureTech, Ltd. under the terms of the license agreement entered into on Oct 23, 2014.
MDVN: 99.23 (+1.23), MRK: 57.46 (+0.25), AMGN: 160.67 (+3.15), BMY: 59.15 (-0.01)

Aerie: A Brilliant Future, Derisking In Progress, And The Making Of A Major Ophthalmic Pharmaceutical
Northern Fundamentals - at Seeking Alpha - Tue Dec 23, 11:45AM CST

AGN: 210.12 (+0.95), VRX: 140.33 (-0.22), PFE: 31.42 (-0.03), MRK: 57.46 (+0.25), AERI: 29.49 (+1.23), NVS: 93.91 (+0.66)

Indexes Turn Mixed On Data; Celgene Dives
at Investor's Business Daily - Tue Dec 23, 9:43AM CST
Stocks backed off early gains and were mixed early Tuesday as investors wrestled through a jumble of economic news. The Dow Jones industrial average rose 0.4% and the S&P 500 added 0.2% as both indexes reached new highs. The Nasdaq shed its early...
DDS: 122.53 (+0.53), BIIB: 340.89 (+5.13), JNJ: 104.59 (+0.31), ABG: 77.12 (+0.43), GILD: 91.29 (+1.84), PFE: 31.42 (-0.03), MRK: 57.46 (+0.25), AMGN: 160.67 (+3.15), CELG: 109.60 (+3.48)

Jim Cramer on the Markets: Some Stocks You Just Can't Ignore
at The Street - Tue Dec 23, 9:03AM CST
And stop chasing stocks that won't let you in.
FDX: 176.42 (-0.52), MMM: 166.96 (+0.09), SWKS: 74.32 (+0.92), NKE: 96.29 (+0.32), HON: 101.96 (-0.02), DIS: 94.42 (-0.27), BA: 131.24 (+1.21), MS: 38.81 (-0.14), AA: 15.77 (+0.04), CBST: 100.29 (-0.09), MRK: 57.46 (+0.25), COST: 143.65 (-0.50), CVS: 97.89 (+0.02), MCD: 93.83 (-0.39), GOOGL: 536.93 (-1.84), ROST: 92.72 (-0.60)

Who Is The Devil? Will Gilead Fall Or Soar In 2015?
Pharma Doc - Seeking Alpha - Tue Dec 23, 6:27AM CST
On December 19, 2014, Abbvie's (NYSE: ABBV ) Viekira Pak received US approval for HCV GT1 patients with or without ribavirin with a minimum of 12 weeks of treatment for a cost of $83.3k. As an avid contributor in this area, I wrote a comprehensive...
JNJ: 104.59 (+0.31), ESRX: 85.48 (-0.40), GILD: 91.29 (+1.84), MRK: 57.46 (+0.25), ABBV: 66.21 (+1.86), BMY: 59.15 (-0.01), ENTA: 49.04 (+0.06)

Cubist's Antibiotic Zerbaxa Wins FDA Nod for cUTI and cIAI - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 22, 3:30PM CST
Cubist's (CBST) antibiotic, Zerbaxa gained FDA approval for the treatment of adults with complicated urinary tract infections and complicated intra-abdominal infections.
ACT: 254.20 (-1.68), CBST: 100.29 (-0.09), MRK: 57.46 (+0.25), BIOD: 1.36 (-0.04)

Harris & Harris Group Notes Publicly Traded Portfolio Company Enumeral Biomedical's Collaboration With Merck
GlobeNewswire - Mon Dec 22, 11:28AM CST
Harris & Harris Group, Inc. (Nasdaq:TINY), an investor in transformative companies enabled by disruptive science, notes that its publicly traded portfolio company, Enumeral Biomedical Holdings, Inc., announced that it has signed an oncology-focused collaborative study agreement with Merck, known as MSD outside the United States and Canada, through a subsidiary. The collaborators will use Enumeral's human approach to interrogating the tumor microenvironment in colorectal cancer tissues obtained directly from patients in order to identify functional cellular responses to immuno-oncology therapies being developed by Merck. Enumeral's human-driven immune profiling platform may increase the probability of finding rare immune cells associated with disease or drug response through improved efficiency and sensitivity. Studying rare cells obtained directly from human patients for their functional responses can potentially lead to identification of those patients responsive to a therapy, while elucidating the underlying cellular basis for such a response. Under the terms of the agreement, Enumeral will receive R&D funding and is eligible to receive undisclosed future milestone payments if certain goals are achieved. Merck has exclusive rights to data related to its proprietary compounds that are generated from the studies. You may access Enumeral's press release at http://www.enumeral.com/news-events/pr-2014-12-18.php.
TINY: 2.95 (-0.01), MRK: 57.46 (+0.25)

Achillion Pharma Takeout Less Likely Following Subpar Hep C Drug Results
at The Street - Mon Dec 22, 10:36AM CST
These Achillion results aren't great because the speed at which drugs kill the hepatitis C virus matters. Slower-acting drugs leave patients vulnerable to viral rebound or relapse.
GILD: 91.29 (+1.84), ACHN: 13.06 (+1.22), MRK: 57.46 (+0.25)

Next Support Level for Merck (MRK) is $58.61
Comtex SmarTrend(R) - Mon Dec 22, 10:12AM CST
Shares of Merck (NYSE:MRK) have bearishly opened below the pivot of $59.50 today and have reached the first support level of $59.09. Investors may be interested in a cross of the next downside pivot targets of $58.61 and $57.72.
MRK: 57.46 (+0.25)

Stocks Struggle To Hold Gains; Alaska Air, Spirit Up
at Investor's Business Daily - Mon Dec 22, 9:34AM CST
Stocks got off to a mixed start, but quickly turned positive in the shortened holiday week, with drugmakers showing particular weakness at Monday's open. The Dow Jones industrial average led, up 0.4%. The Nasdaq backed out of early losses to a 0.2%...
BIIB: 340.89 (+5.13), ESRX: 85.48 (-0.40), SAVE: 75.68 (+1.52), GILD: 91.29 (+1.84), MRK: 57.46 (+0.25), AMGN: 160.67 (+3.15), ABBV: 66.21 (+1.86), ALK: 58.72 (+1.97), REGN: 400.12 (+6.07), CELG: 109.60 (+3.48)

Could Gilead Sciences, Inc. Be a Top Stock in 2015?
Sean Williams, The Motley Fool - Motley Fool - Mon Dec 22, 8:46AM CST
GILD data by YCharts Despite last weeks' oil-induced swoon, the S&P 500 is still up by 8% for the year. But don't bother bragging about this to Gilead Sciences shareholders -- through the weekend, Gilead shares had nearly quintupled the...
GILD: 91.29 (+1.84), MRK: 57.46 (+0.25), ABBV: 66.21 (+1.86)

BARDA awards Ebola vaccine contract to NewLink Genetics
Seeking Alpha - at Seeking Alpha - Mon Dec 22, 7:44AM CST

MRK: 57.46 (+0.25), NLNK: 39.08 (+1.36)

NewLink Genetics, Merck Collaboration to Manufacture Ebola Vaccine Candidate Supported by $30 Million Government Award
GlobeNewswire - Mon Dec 22, 7:00AM CST
NewLink Genetics Corporation (Nasdaq:NLNK) and Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that the Biomedical Advanced Research and Development Authority (BARDA) of the United States Department of Health and Human Services (HHS) has awarded NewLink Genetics' wholly-owned subsidiary, BioProtection Systems, as the prime contractor in a $30 million contract to support the manufacturing and development activities of its investigational rVSV-EBOV (Ebola) vaccine candidate, including clinical development through a new 330-person Phase Ib study.
MRK: 57.46 (+0.25), NLNK: 39.08 (+1.36)

Merck begins tender offer to acquire Cubist
M2 - Mon Dec 22, 6:43AM CST
Healthcare company Merck (NYSE:MRK) said on Friday that its subsidiary has started a cash tender to purchase all outstanding shares of common stock of Cubist Pharmaceuticals (NasdaqGS:CBST).
CBSTZ: 0.06 (+0.01), CBST: 100.29 (-0.09), MRK: 57.46 (+0.25)

Could the Next Generation of Diabetes Treatments Be Found in This Illegal Drug?
Sean Williams, The Motley Fool - Motley Fool - Sun Dec 21, 10:41AM CST
Heart disease and cancer may be the two most common direct causes of death in the United States, but a chronic disease that now affects 29.1 million people in this country and is a prime risk factor for heart disease, cancer, and...
JNJ: 104.59 (+0.31), GWPH: 68.08 (+1.82), MRK: 57.46 (+0.25), MNKD: 5.68 (+0.18)

Exciting News: A Game-Changing Shingles Vaccine Could Be On Its Way
Todd Campbell, The Motley Fool - Motley Fool - Sun Dec 21, 6:14AM CST
Source: GlaxoSmithKline plc GlaxoSmithKline  reported late stage trial results for a promising new vaccine for the prevention of shingles that could help millions of people, and in the process win away sales from Merck & Co .'s shingles...
PFE: 31.42 (-0.03), MRK: 57.46 (+0.25), GSK: 42.85 (+0.11)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

AR Cards in Casino Gaming: A High-Stakes Revolution

Updated Category News Views 31

A New Breed of Casino Experience Walk into a casino today, and you might just enter a whole new reality. No, this isn’t a cheesy magician’s trick or a glitzy PR stunt—this is the real deal brought to you by augmented reality (AR) trading cards. Imagine the slots you love wrapped in a sci-fi movie where characters leap out, tap you on the shoulder, and call you by...

Continue Reading
Stephanie L. Beiermann Shines in HR Consulting Honors

Updated Category News Views 61

Celebrating a Star in Payroll Optimization Ah, the name Stephanie L. Beiermann’s been making the rounds lately, catching eyes with her lauded expertise in payroll optimization and human resources. This recognition doesn’t come out of thin air—no, it’s anchored on a solid foundation of over 25 years of cutting through the fluff to sharpen operational edges. We’re...

Continue Reading
Cracking Life Insurance Needs: John Dorsa's Insights

Updated Category News Views 48

Life Insurance: A Necessary Puzzle Life’s uncertainties have a way of putting a wrench in our plans, and nothing screams uncertainty like figuring out life insurance. But fret not! HelloNation’s got insights on this financial maze, and they’ve roped in insurance pro John Dorsa from Ridgeland to help out. Calculating Coverage Needs Forget the one-size-fits-all...

Continue Reading
Amdocs Faces a Storm: Investor Alert as Legal Probe Begins

Updated Category News Views 35

Amdocs' Recent Crisis: What Investors Need to Know Lately, it seems Amdocs Limited (NASDAQ: DOX) has found itself knee-deep in a situation that could make seasoned investors cringe. November shone some harsh light on the company's operations, a move that’s attracted attention from Schall, Brown & Schwartz LLP (“SBS”), a name not exactly foreign to shareholder...

Continue Reading
Hermes AI: A New Era in Market Analysis?

Updated Category News Views 44

Revolution or Just Another App? In a world where stock market insights are as cryptic as hieroglyphs to the average Joe, here comes the Hermes AI Analyzer, breaking onto the scene and promising to translate Wall Street's complex lingo into plain, simple language. It's the brainchild of Turkish engineer Umut Tugrul, who has spent decades in the trenches of software...

Continue Reading
Kinross Gold Faces Class Action Over Misleading Forecasts

Updated Category News Views 51

A Golden Opportunity Gone Wrong Well, it looks like Kinross Gold Corporation (NYSE: KGC) has stuck its foot in it again. This time, they're in hot water over claims that don't exactly hold up under scrutiny. If you're holding KGC, you've probably heard about the fresh class action lawsuit alleging they misled investors about their production targets. Naturally, the...

Continue Reading
NVCA Refreshes Key Venture Legal Documents for 2026

Updated Category News Views 71

Keeping Pace with Evolving Venture Norms Change never lets up in the fast-paced world of venture capital, does it? Just when you think you've got the rules figured out, the game shifts. This time, it's the National Venture Capital Association (NVCA) shaking things up. They've given a facelift to seven of their model legal documents, a move that reshapes the legal...

Continue Reading
Silvi's Expansion Push: New Terminal in Wilmington

Updated Category News Views 55

Silvi's Latest Bet on the Southeast You know, sometimes you get a gut feeling that a company is rolling out chess moves instead of checkers. That’s what Silvi Materials is up to with their new project in Wilmington. It’s not just some fancy cement terminal—it’s a calculated expansion into the heart of the Southeast construction market. The Port of Wilmington’s...

Continue Reading
Older Adults Embrace Cosmetic Dentistry for Confidence

Updated Category News Views 139

Why the Shift to Cosmetic Dentistry Later in Life? Aging doesn't just wrinkle your skin; it affects your smile too. Dr. Joseph T. Sumrall and Dr. Gran Sumrall, the dental gurus of Warner Robins, Georgia, are laying out why more adults are jumping on the cosmetic dentistry bandwagon as they age. Spoiler: It ain't about getting a movie-star grin but something much deeper....

Continue Reading
FDA Changes Shake Up Medtech Inspections Landscape

Updated Category News Views 124

Inspecting the Changing FDA Landscape If you’ve been treating FDA inspections like a ride down memory lane, it's time for a wake-up call. What F. David Rothkopf plans to tell the medical device teams at the MEDevice Silicon Valley event is simple: the game has changed. The FDA’s Quality Management System Regulation (QMSR) that kicked in on February 2, 2026, isn’t...

Continue Reading

Top 5 Most Recently Viewed Articles

Cytek Biosciences Prepares for Q2 2025 Financial Results Report

Updated Category News Views 214

Cytek Biosciences Plans Financial Disclosure for Second Quarter 2025 Cytek Biosciences, Inc. (NASDAQ: CTKB), based in Fremont, California, has dynamic news for stakeholders. The company is set to disclose its financial results for the second quarter of 2025 on August 6, 2025. This critical deadline follows the market closure that day, allowing for a comprehensive analysis...

Continue Reading
Alliance Trust PLC Shares Up: Latest NAV Per Share Insights

Updated Category News Views 171

Alliance Trust PLC Alliance Trust PLC's recent trading data dropped some key numbers that had traders buzzing. The Net Asset Value (NAV) per ordinary share hit the screens, giving everyone a fresh angle on how the company was really performing in a choppy market. NAV Breakdown: What's It Telling Us? Here's how the NAV shook out on the latest report: Valued on a Bid Price...

Continue Reading
Man Group Investment Insights: Spirent Communications and Trends

Updated Category News Views 199

Investment Insights from Man Group regarding Spirent Communications In today’s evolving market, understanding the dynamics between significant firms like Man Group PLC and Spirent Communications plc is vital for investors. This disclosure provides a snapshot of Man Group’s holdings and interests, particularly in relation to investing more than 1% in relevant...

Continue Reading
Sunny Lowe Joins Prime Mining Corp's Board of Directors

Updated Category News Views 221

Prime Mining Corp. (TSX: PRYM) (Other OTC: PRMNF) (Frankfurt: O4V3) has recently appointed Sunny Lowe to its Board of Directors. This announcement highlights a strategic move by the company to strengthen its leadership team as it continues its key projects, particularly the Los Reyes Project. Welcome to Sunny Lowe Murray John, Chair of the Board, expressed enthusiasm...

Continue Reading
Spotlight on Magnificent 7 Stocks: Opportunities in a Turbulent Market

Updated Category News Views 190

Market Overview: Understanding the Current Landscape The technology sector has seen major fluctuations recently, prompting discussions about the best investment opportunities. Economic uncertainties and market instability have resulted in significant stock losses, making this a pivotal moment for investors. The backdrop of Trump’s trade policies adds another layer of...

Continue Reading